Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Claudia Monaco, of the Kennedy Institute, is the 2015 Oxford-Harrington Scholar.

As a clinician-scientist, Professor Monaco has dedicated her career to the discovery of new treatments for cardiovascular disease (CVD). Her work was pioneering in looking at CVD within the area of inflammation, using a unique approach to test efficacy in human atherosclerosis – a condition where arteries become blocked by fatty substances.

CVD is a big health problem and the second leading cause of death in the UK, representing 28% of all deaths in 2012. In addition, there were more than 1.6 million episodes related to cardiovascular disease in NHS hospitals, with more than £6.8 billion being spent on treating CVD within the NHS in England.

Professor Monaco’s research aims to change standard of care and improve health for people with CVD, by bringing new medicines into the clinical setting.

The Oxford-Harrington Scholarship Programme was set up in 2014 as a partnership between the Harrington Discovery Institute (Cleveland, USA) and the University of Oxford to advance highly promising Oxford supported drug discovery projects.

The rate of drug development is now slower than it used to be, with pharmaceutical companies and investors waiting to invest until the efficiency of a drug has been confirmed. This leaves a gap in the intermediate stages of research and development and has discouraged clinical scientists from pursuing their ideas.

The Oxford-Harrington Scholarship will close this gap by supporting clinical scientists whose ideas have great potential to become new treatments, with pre-clinical drug research and clinical trials in the early stages. It will also provide the drug development infrastructure needed to turn a discovery into a medicine.

The first Oxford-Harrington scholar was Professor Alison Simmons, whose aims were to undertsnad how inflammation damages the gut in Crohn’s disease, a condition that affects 1 in 200 people.

You can read more about the 2015 Oxford-Harrington Scholar here.

 

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.